Final Thoughts and Future Innovations

EP: 1.Review of Latest Guidelines on Quad Therapy in NDMM

EP: 2.Classifying High-Risk Patients With NDMM

EP: 3.Pretesting Prior to Quad Therapy for NDMM

EP: 4.Overview of the ADVANCE Study: Methodology and Design

EP: 5.Expert Perspectives on the Design of the ADVANCE Trial

EP: 6.Key Efficacy Results From ADVANCE: MRD Negativity Stratified by Age and Risk

EP: 7.Transplant Eligible vs Ineligible: Clinical Implications

EP: 8.Safety Signals of Daratumumab + KRd: Real-World Translation

EP: 9.Risk of Infection and IVIG Use

Now Viewing

EP: 10.Final Thoughts and Future Innovations

Panelists discuss how ongoing advances in newly diagnosed multiple myeloma (NDMM) therapy are transforming patient outcomes through precision-based treatment, sustained minimal residual disease (MRD) suppression, and better quality of life. They foresee a continued shift toward tailored therapy durations guided by MRD results and patient-specific biology. The discussion highlights innovations such as bispecific antibodies, chimeric antigen receptor T-cell therapy, and targeted maintenance approaches, predicting these will further extend remission durability and reduce relapse rates.